| abstract |
The present invention provides biomarkers for the treatment of hemangioma, and specifically, provides a method and a kit for effectively evaluating and predicting the efficacy of itraconazole in treating infantile hemangioma by using the expression level of biological factors, wherein the biological factors are: One or more of VEGF-A, PDGF-A, PDGF-D, HES, HEY1, HIF3A, IL-8, TNF-A or FGF. It is of great significance for the judgment of the efficacy of infantile hemangioma, the evaluation of prognosis and the guidance of the course of medication. |